Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.
The Director, HCP Marketing - DM1 will lead the development and execution of HCP-focused strategies and initiatives that empower care providers who treat Myotonic Dystrophy. The role is pivotal in driving impactful HCP engagement programs that support successful market entry and long-term adoption.
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.
Beam Therapeutics